Cytolon AG Global Cord Program Partners with Mediware for Stem Cell, Cord Blood Bank Solution
Mediware and Cytolon will work together to improve the ease of hematopoietic stem cell matching in cord blood banking
LENEXA, Kan.--(BUSINESS WIRE)--Mediware Information Systems, Inc. and Cytolon AG agreed to collaborate on improving IT tools for banking and matching of hematopoietic stem cells derived from umbilical cord blood donations.
“Mediware is a great partner. The collaboration between our complementary IT solutions will connect matches across the world and help save lives with stem cell therapies.”
Umbilical cord blood hematopoietic stem cells are most often transplanted to patients with certain blood or bone marrow cancers, such as multiple myeloma or leukemia. The best human leukocyte antigen (HLA) match must be selected for transplants to reduce the risk of graft-versus-host disease and other complications of allogeneic hematopoietic stem cells transplantation.
Cytolon AG’s Internet-based platform, CordMatch® matches cord blood units globally to allow for secure and cost-free communication between clinicians and coordinators with the UCB product providers. This innovative platform enables immediate and comprehensive search on all registered UCB data according to the clinician’s protocol and provides comprehensive information reports on relevant stem cell products in real-time for informed decision making. CordMatch is a patented Class 1 medical device registered in both Europe and the U.S.
This new collaboration will bring substantially greater connectivity to the cord blood banks already using Mediware's existing cord blood banking software. The collaboration will expand Cytolon's customer base and increase the number of cord blood units listed for transplant.
The Transtem™ software system from Mediware provides complete process management from online donor registration and account creation, through product collection, manufacturing, storage, testing, label generation and release – all within a single Web-based system. Together, CordMatch and Transtem will provide an enhanced user experience for listing, searching and selecting cord blood products for transplant while increasing process efficiency and safety.
“We see great opportunities for our customers by working together with Mediware,” said Thomas Klein, the founder and CEO of Cytolon. “Mediware is a great partner. The collaboration between our complementary IT solutions will connect matches across the world and help save lives with stem cell therapies.”
About Mediware Information Systems, Inc.
Mediware delivers interoperable best-of-breed software systems that improve efficiencies and address safety concerns, enabling healthcare organizations to improve care processes while decreasing costs. Core Mediware solutions include blood management technologies for hospitals and blood centers; cell therapy solutions for cord blood banks, blood and marrow transplant centers, cellular therapy laboratories and regenerative medicine programs; medication management solutions for hospitals, behavioral health facilities, infusion and specialty pharmacy providers; business intelligence-based performance management solutions for clinical, regulatory and financial aspects of the broader healthcare market; and rehabilitation therapy and respiratory care solutions. For more information about Mediware products and services, visit our website at www.mediware.com.
CordMatch is a high performance, Internet-based platform that matches cord blood units to the patients who need them. CordMatch® is unique as it integrates product search, matching, selection, logistics and follow up steps in a single platform.
Cytolon AG is a technology oriented service provider positioning itself as the first company worldwide to offer intelligent internet platforms that will become necessary for the field of personalized medicine. Cytolon's first product is an internet-based matching platform, CordMatch®. CordMatch offers efficient cost saving solutions to transplant centers, donor registries, cord blood banks, and pharmaceutical companies which make it possible to provide individually matched stem cell preparations for a high number of cases worldwide. Thomas Klein founded Cytolon AG in 2008. In 2009 Cytolon was awarded the “most promising company launched-Award” by Deutsche Bank, Hasso Plattner Ventures. Cytolon is a member of the Association of Research-Based Pharmaceutical Companies (www.vfa.de) and the Federal Association for Information Technology, Telecommunications and New Media (www.bitkom.org) as well as the Personalized Medicine Coalition in Washington, USA (www.personalizedmedicinecoalition.org). Further information can be found at www.cytolon.com.